Document is current
Any future updates will be listed below
-
Authors
Pratley, Richard E. https://orcid.org/0000-0002-2912-1389
Denham, Douglas Scott
Trivedi, Rupal
Watkins, Elaine
Connery, Lisa
Barnes, Jennifer
Yu, Dongzi
Hong, Janet
Simard, Christopher
Umans, Kimberly https://orcid.org/0009-0006-2717-8265
Liu, Lan
Tirucherai, Giridhar S.
Marantz, Jing L.
-
Funding
Funding for this research was provided by:
Scholar Rock, Inc.
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 1 May 2026
First Online: 8 June 2026
Competing interests
: R.E.P. declares speaker fees from Abbott, Corcept, Lilly and Novo Nordisk; consulting fees from AbbVie, Amgen, Bayer AG, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Corcept, Endogenex, Gasherbrum Bio, Genprex, Getz Pharma, Intas Pharmaceuticals, Lilly, Novo Nordisk, Pfizer, Sun Pharmaceutical Industries and Verdiva; and research grants from Boehringer Ingelheim, Carmot Therapeutics, Dompe, Endogenex, Lilly, Novo Nordisk and Sanofi. D.S.D. reports no conflicts related to this work. R.T. reports no conflicts related to this work. E.W. reports no conflicts related to this work. L.C. has served on advisory boards for Boehringer Ingelheim, Lilly and Intarcia and has received research funding from Amgen, Argo, AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, Regeneron, Regor, Roche, Scholar Rock, Structure/Gasherbrum, Vanda, Verdiva, Viking and Zealand. D.Y., J.H., C.S., K.U., L.L., G.S.T. and J.L.M. are employees of Scholar Rock, Inc. and may hold stock/stock options in the company. J.B. was affiliated with Scholar Rock at the time the study was conducted.
